| Cat.No. | Name | Information |
|---|---|---|
| M4838 | TAK-242 (Resatorvid) | Resatorvid (TAK-242) is a selective TLR4 signaling inhibitor. Resatorvid inhibited the production of NO, TNF-α and IL-6 with IC50 values of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid down-regulates the expression of MyD88 and TRIF signaling molecules downstream of TLR4. Resatorvid inhibits autophagy and plays a key role in a variety of inflammatory diseases. |
| M11408 | Hydroxychloroquine | Hydroxychloroquine is a synthetic antimalarial agent that also inhibits Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine effectively inhibited SARS-COV-2 infection. |
| M9063 | TLR2-IN-C29 | C29 is a Toll-like receptor 2 (TLR2) inhibitor. C29 blocked HTLR2/1 and HTLR2/6 with IC50 values of 19.7 and 37.6 μM, respectively. |
| M42066 | Polyinosinic acid | Polyinosinic acid is a single stranded homonucleic acid, which is a Toll-like Receptor 3 (TLR3) agonist. |
| M5062 | Polyinosinic:polycytidylic acid | Polyinosinic:polycytidylic acid (poly I:C) is a synthetic polyinosinic-polycytidylic acid double-stranded RNA. Polyinosinic-polycytidylic acid (Poly (I:C)) is an agonist of toll-like receptor (TLR)-3. Polyinosinic-polycytidylic acid has protective effects against cerebral ischemia/reperfusion (I/R) injury and can be used as vaccine adjuvant to enhance innate and adaptive immune responses. |
| M2728 | Vesatolimod (GS-9620) | Vesatolimod (GS-9620) is an effective, selective, oral toll-like receptor 7 (TLR7) agonist with an EC50 value of 291 nM. |
| M42063 | TLR7/8 agonist 8 | TLR7/8 agonist 8 is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. |
| M42062 | Tilsotolimod sodium | Tilsotolimod (sodium) is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. |
| M40904 | ODN TTAGGG | ODN TTAGGG is an inhibitory oligodeoxynucleotide (ODN) as well as a TLR9, AIM2 and cGAS antagonist with immunosuppressive activity, which inhibits the activation of the AIM2 inflammasome by competing with DNA, as well as the activation of cGAS. It can be used in the study of autoimmune diseases such as lupus erythematosus. Sequence: 5'-T-T-T-A-G-G-G-T-T-T-T-A-G-G-G-T-T-T-A-G-G-G-T-T-T-A-G-G-G-T-T-T-A-G-G-G-3'. |
| M30937 | ODN 1018 | ODN 1018 (1018 ISS), an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5′-TGACTGTGAACGTTCGAGATGA-3′. |
| M30420 | 3M-011 | 3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action. |
| M29946 | L48H37 | L48H37 is an analog of Curcumin with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment. |
| M29890 | MMG-11 | MMG-11 is a potent and selective human TLR2 antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC50s of 1.7 µM for Pam3CSK4-induced hTLR2/1 and 5.7 µM for Pam2CSK4-induced hTLR2/6 responses. |
| M29713 | CL075 | CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively. |
| M29589 | Polvitolimod | Polvitolimod is a TLR7 agonist for research of cancer and infectious disease. |
| M29469 | SM-360320 | SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response. SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity. |
| M28075 | TLR7/8 agonist 1 | TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline. |
| M28000 | GSK1795091 | GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. |
| M27994 | TLR7 agonist 3 | TLR7 agonist 3 (Compound 2) is a potent agonist of toll-like receptor 7 (TLR7). TLR7 has an important role in immune activation processes and represents an emerging agent discovery target for the development of immunomodulators. |
| M27993 | BBIQ | BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses. |
| M27867 | Gardiquimod diTFA | Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM. |
| M27847 | TMX-201 | TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research. |
| M27651 | Gardiquimod | Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM. |
| M25485 | Diprovocim | Diprovocim is a potent human and mouse Toll-like receptor (TLR)1/TLR2 agonist, which exhibited an EC50 of 110 pM in human THP-1 cells and 1.3 nM in primary mouse peritoneal macrophages. Diprovocim activates downstream MAPK and NF-κB signaling pathway. |
| M25199 | Paridiprubart | Paridiprubart (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart has the potential for the research of rheumatoid arthritis. |
| M24686 | Tomaralimab | Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
